190 related articles for article (PubMed ID: 29419687)
21. Concomitant sarcoidosis and papillary thyroid cancer with severe hypercalcaemia as the main symptom.
Riis MG; Juhl KS; Bruun JM
BMJ Case Rep; 2018 Jun; 2018():. PubMed ID: 29884710
[TBL] [Abstract][Full Text] [Related]
22. Routine central lymph node dissection with total thyroidectomy for papillary thyroid cancer potentially minimizes level VI recurrence.
Hall CM; Snyder SK; Maldonado YM; Lairmore TC
Surgery; 2016 Oct; 160(4):1049-1058. PubMed ID: 27521047
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
Lichtman SM; Niedzwiecki D; Barcos M; Carlisle TL; Cooper MR; Johnson JL; Peterson BA
Ann Oncol; 2000 Sep; 11(9):1141-6. PubMed ID: 11061609
[TBL] [Abstract][Full Text] [Related]
24. [Diagnosis and treatment of primary testicular non-Hodgkin lymphoma].
Romics M; Demeter J; Romics I; Nyirády P
Orv Hetil; 2014 Jan; 155(2):69-71. PubMed ID: 24389323
[TBL] [Abstract][Full Text] [Related]
25. Two Cases of Synchronous Hodgkin Lymphoma and Papillary Thyroid Carcinoma in 18 F-FDG PET/CT.
Wang R; Cai H; Liu C; Lv Z; Ma C
Clin Nucl Med; 2024 Jul; 49(7):650-651. PubMed ID: 38689445
[TBL] [Abstract][Full Text] [Related]
26. Synchronous primary malignancies of papillary thyroid carcinoma and Hodgkin lymphoma: Interventions and outcome.
Abd Rahim A; Muhammad R; Ismail F; Wong YP; Che Abdul Aziz R; Chong GY; Wan Jamaludin WF
Malays J Pathol; 2023 Aug; 45(2):275-283. PubMed ID: 37658537
[TBL] [Abstract][Full Text] [Related]
27. Differentiated thyroid cancer: role of the lymph node dissection.
Caglià P; Zappulla E; Costa S; Tracia M; Veroux M; Russo V; Borzì L; Lucifora B; Patanè G; Tracia L; Amodeo C
G Chir; 2010; 31(6-7):293-5. PubMed ID: 20646374
[TBL] [Abstract][Full Text] [Related]
28. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.
Hüttmann A; Rekowski J; Müller SP; Hertenstein B; Franzius C; Mesters R; Weckesser M; Kroschinsky F; Kotzerke J; Ganser A; Bengel FM; La Rosée P; Freesmeyer M; Höffkes HG; Hertel A; Behringer D; Prange-Krex G; Griesshammer M; Holzinger J; Wilop S; Krohn T; Raghavachar A; Maschmeyer G; Brink I; Schroers R; Gaska T; Bernhard H; Giagounidis A; Schütte J; Dienst A; Hautzel H; Naumann R; Klein A; Hahn D; Pöpperl G; Grube M; Marienhagen J; Schwarzer A; Kurch L; Höhler T; Steiniger H; Nückel H; Südhoff T; Römer W; Brinkmann M; Ose C; Alashkar F; Schmitz C; Dürig J; Hoelzer D; Jöckel KH; Klapper W; Dührsen U
Ann Hematol; 2019 Apr; 98(4):897-907. PubMed ID: 30610279
[TBL] [Abstract][Full Text] [Related]
29. Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.
Dührsen U; Müller S; Hertenstein B; Thomssen H; Kotzerke J; Mesters R; Berdel WE; Franzius C; Kroschinsky F; Weckesser M; Kofahl-Krause D; Bengel FM; Dürig J; Matschke J; Schmitz C; Pöppel T; Ose C; Brinkmann M; La Rosée P; Freesmeyer M; Hertel A; Höffkes HG; Behringer D; Prange-Krex G; Wilop S; Krohn T; Holzinger J; Griesshammer M; Giagounidis A; Raghavachar A; Maschmeyer G; Brink I; Bernhard H; Haberkorn U; Gaska T; Kurch L; van Assema DME; Klapper W; Hoelzer D; Geworski L; Jöckel KH; Scherag A; Bockisch A; Rekowski J; Hüttmann A;
J Clin Oncol; 2018 Jul; 36(20):2024-2034. PubMed ID: 29750632
[TBL] [Abstract][Full Text] [Related]
30. Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Cancer: Clinical Lessons from a Community-Based Endocrine Surgical Practice.
Golding A; Shively D; Bimston DN; Harrell RM
Int J Surg Oncol; 2017; 2017():4689465. PubMed ID: 28487771
[No Abstract] [Full Text] [Related]
31. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.
Press OW; Unger JM; Braziel RM; Maloney DG; Miller TP; LeBlanc M; Gaynor ER; Rivkin SE; Fisher RI
Blood; 2003 Sep; 102(5):1606-12. PubMed ID: 12738671
[TBL] [Abstract][Full Text] [Related]
32. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.
Dahele M; Ung YC; Ehrlich L; Silverberg J; Balogh J; Wong CS
J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):712-7. PubMed ID: 19128681
[TBL] [Abstract][Full Text] [Related]
33. Radio-guided selective compartment neck dissection improves staging in papillary thyroid carcinoma: a prospective study on 345 patients with a 3-year follow-up.
Carcoforo P; Portinari M; Feggi L; Panareo S; De Troia A; Zatelli MC; Trasforini G; Degli Uberti E; Forini E; Feo CV
Surgery; 2014 Jul; 156(1):147-57. PubMed ID: 24929764
[TBL] [Abstract][Full Text] [Related]
34. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
35. [Clinical treatment of metastatic papillary thyroid carcinoma in cervical lymph nodal with occult primary sites].
Pang YJ; Chen XH; Zhang JY; Gao JL
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jul; 31(13):1013-1016. PubMed ID: 29798166
[No Abstract] [Full Text] [Related]
36. A Bayesian approach to a patient with a residual mass after treatment for non-Hodgkin's lymphoma of the thyroid.
Bibb J; Hromas R; Rabinowitz I
J Clin Oncol; 2005 Dec; 23(34):8911-3. PubMed ID: 16314654
[No Abstract] [Full Text] [Related]
37. Risk factors and the preoperative assessment of right para-oesophageal lymph node metastasis in right lobe papillary thyroid carcinoma: A case series.
Qu Y; Zhang H; Zhang P; Dong W; He L; Sun W; Liu J
Int J Surg; 2017 Jun; 42():123-127. PubMed ID: 28473292
[TBL] [Abstract][Full Text] [Related]
38. [Prediction and investigation of the potential risk factors for the upper mediastinal metastasis of papillary thyroid carcinoma].
Liu Y; Xu SY; Liu K; Wang XL; Liu SY; Xu ZG; Liu J
Zhonghua Zhong Liu Za Zhi; 2021 Apr; 43(4):477-483. PubMed ID: 33902211
[No Abstract] [Full Text] [Related]
39. [Clinical study on papillary thyroid carcinoma presenting with lymph node metastasi].
Mizumachi T; Oridate N; Homma A; Nagahashi T; Furuta Y; Fukuda S
Nihon Jibiinkoka Gakkai Kaiho; 2004 Aug; 107(8):750-5. PubMed ID: 15457986
[TBL] [Abstract][Full Text] [Related]
40. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
